Latest news

• GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours

  GlaxoSmithKline’s (GSK) dostarlimab – an investigational PD-1 inhibitor – has demonstrated promising results in patients with heavily pre-treated solid cancer tumours. ... This data shows that dostarlimab may become an important new treatment

• GSK pays $50m upfront to tap Immatics’ cell therapy platform

  for multiple myeloma and dostarlimab for endometrial cancer.

• GSK boosts outlook thanks to strong respiratory and vaccine sales

  GSK also highlighted the success of its new oncology medicine Dostarlimab, which is used in the treatment of advanced or recurrent endometrial cancer.

• Advair generics and acquisitions to hit GSK in 2019

  These are its BCMA targeting candidate in fourth-line multiple myeloma, and Tesaro’s Zejula for first line maintenance ovarian cancer and PD-1 dostarlimab for endometrial cancer.

• Analysts lukewarm on GSK’s new cancer acquisition

  He does feel there is potential to position Zejula as combination therapy with checkpoint inhibitors, including dostarlimab (TSR-042), Tesaro’s own anti-PD-1 monoclonal antibody, but overall thinks the